Effect of short‐term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of short‐term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-08-02
DOI
10.1111/dom.14505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomised controlled study of high intensity exercise as a dishabituating stimulus to improve hypoglycaemia awareness in people with type 1 diabetes: a proof-of-concept study
- (2020) Catriona M. Farrell et al. DIABETOLOGIA
- Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
- (2020) Thorsten Siegmund et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2
- (2019) Chantal Mathieu et al. DIABETES CARE
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
- (2019) Tadej Battelino et al. DIABETES CARE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- Genetic determinants of impaired awareness of hypoglycemia in type 1 diabetes
- (2017) Bas J. Schouwenberg et al. Pharmacogenetics and Genomics
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial
- (2016) Cornelis A J van Beers et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
- (2015) T. R. Pieber et al. DIABETES OBESITY & METABOLISM
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Self-reported non-severe hypoglycaemic events in Europe
- (2013) C. G. Östenson et al. DIABETIC MEDICINE
- Patient experience of hypoglycaemia unawareness in Type 1 diabetes: are patients appropriately concerned?
- (2011) H. A. Rogers et al. DIABETIC MEDICINE
- Opioid Receptor Blockade Improves Hypoglycemia-Associated Autonomic Failure in Type 1 Diabetes Mellitus
- (2011) Septimiu Vele et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Barrier of Hypoglycemia in Diabetes
- (2008) P. E. Cryer DIABETES
- Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes
- (2008) J. Geddes et al. DIABETIC MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started